CytoSorbents Q2 2026 revenue flat at $9.6M; operating loss improves 27%

Cytosorbents Corp

2026-Q2 EPS reported -$0.15 revenue$18,497,000

Revenue $9.6M (unchanged YoY); gross margin 73% (up from 71% YoY).
Operating loss improved 27% to $2.6M; net loss $4.4M ($0.07) vs net income $1.9M ($0.03) in Q2 2025 due to FX.
Adjusted net loss improved 22% to $2.8M ($0.05); adjusted EBITDA loss improved 38% to $1.6M.
Cash burn reduced to $0.4M (incl. $0.2M restructuring); workforce cut 23% since Sep 2025.
Two FDA pre-submission meetings in Aug 2026 for DrugSorb-ATR (Brilinta and DOAC programs).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.